Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Inflammatory Waldenström Macroglobulinemia is associated with clonal hematopoiesis: a multicentric cohort

Blood blood.2024025738.

https://doi.org/10.1182/blood.2024025738

Published: 2024

Includes: Supplemental data

Journal Articles

Inflammatory Waldenström Macroglobulinemia Is Associated with Clonal Hematopoiesis: A Multicentric Cohort

Blood (2024) 144 (Supplement 1): 4343.

https://doi.org/10.1182/blood-2024-193883

Published: 2024

Journal Articles

Characteristics and Outcomes of Adult Patients with T Prolymphocytic Leukemia: A Real World Study of the French Innovative Leukemia Group (FILO)

Blood (2022) 140 (Supplement 1): 1485–1487.

https://doi.org/10.1182/blood-2022-157399

Published: 2022

Journal Articles

Long-Term Follow-up of Bendamustine Plus Rituximab Regimen in 69 Treatment Naïve (TN) Patients with Waldenström Macroglobulinemia, a Study on Behalf of the French Innovative Leukemia Organization (FILO)

Kamel Laribi, Stéphanie Poulain, Lise Willems, Fatiha Merabet, Charles Herbaux, Damien Roos Weil, Alix Baugier de Materre, Xavier Roussel, Sabine Tricot, Jehan Dupuis, Ronan Le Calloch, Benoit Bareau, Marie C Béné, Veronique Leblond

Blood (2022) 140 (Supplement 1): 3627–3628.

https://doi.org/10.1182/blood-2022-157394

Published: 2022

Journal Articles

Preliminary Study of Ruxolitinib and Venetoclax for Treatment of Patients with T-Cell Prolymphocytic Leukemia Refractory to, or Ineligible for Alemtuzumab

Charles Herbaux, Stéphanie Poulain, Damien Roos-Weil, Jacques-Olivier Bay, Yann Guillermin, Francois Lemonnier, Kamel Laribi, Sorin Visanica, Jerome Moreaux, Hugo Gonzalez, Maxime Jullien, Abderrazak El Yamani, Houria Debarri, Sophie Godet, Franck Morschhauser, Olivier Tournilhac, Matthew S. Davids, Loic Ysebaert

Blood (2021) 138 (Supplement 1): 1201.

https://doi.org/10.1182/blood-2021-149228

Published: 2021

Journal Articles

BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia

Blood (2021) 137 (25): 3495–3506.

https://doi.org/10.1182/blood.2020007303

Published: 2021

Includes: Supplemental data

Journal Articles

Germline PAX5 mutation predisposes to familial B-cell precursor acute lymphoblastic leukemia

Blood (2021) 137 (10): 1424–1428.

https://doi.org/10.1182/blood.2020005756

Published: 2021

Includes: Supplemental data

Journal Articles

High frequency of clonal hematopoiesis in Erdheim-Chester disease

Fleur Cohen Aubart, Damien Roos-Weil, Marine Armand, Alice Marceau-Renaut, Jean-François Emile, Nicolas Duployez, Frédéric Charlotte, Stéphanie Poulain, Raphael Lhote, Zofia Hélias-Rodzewicz, Véronique Della-Valle, Olivier Bernard, Karim Maloum, Florence Nguyen-Khac, Jean Donadieu, Zahir Amoura, Omar Abdel-Wahab, Julien Haroche

Blood (2021) 137 (4): 485–492.

https://doi.org/10.1182/blood.2020005101

Published: 2021

Includes: Supplemental data

Journal Articles

Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 rearrangement

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-139210

Published: 2020

Journal Articles

Open Label Non-Randomized Phase II Study Exploring «Chemo-Free » Treatment Association with Idelalisib + Obinutuzumab in Patients with Relapsed/Refractory (R/R) Waldenstrom's Macroglobulinemia (MW), a Filo Trial: Results of the Intermediary Analysis of the Induction Phase

Cecile Tomowiak, MD, Kristell Desseaux, Stéphanie Poulain, MD PhD, Charles Herbaux, MD, Aurore Perrot, MD PhD, Beatrice Mahe, MD, Pierre Morel, MD, Olivier Tournilhac, Stephane Lepretre, MD, Thérèse Aurran, MD, Bruno Villemagne, MD, Olivier Casasnovas, MD, Delphine Nollet, Brigitte Dreyfus, MD, Sylvie Chevret, MD PhD, Veronique Leblond, MD PhD

Blood (2019) 134 (Supplement_1): 346.

https://doi.org/10.1182/blood-2019-122826

Published: 2019

Journal Articles

The Broad Spectrum of TP53 Variants in CLL: NGS Analysis of 573 Pathogenic TP53 Variants

Blood (2019) 134 (Supplement_1): 3021.

https://doi.org/10.1182/blood-2019-130907

Published: 2019

Journal Articles

Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia

Christoph Kornauth, Charles Herbaux, MD MSc, Bernd Boidol, PhD, Chantal Guillemette, Patrick Caron, Stéphanie Poulain, MD PhD, Olivier Tournilhac, Marius E Mayerhoefer, Ulrich Jaeger, MD, Stefan Kubicek, Matthew S. Davids, MD, Philipp Bernhard Staber, MD PhD

Blood (2019) 134 (Supplement_1): 3965.

https://doi.org/10.1182/blood-2019-124392

Published: 2019

Journal Articles

Characterizing the Anti-Apoptotic Dependencies of T-Cell Prolymphocytic Leukemia Identifies HDAC and JAK/STAT Pathway Inhibitors As Promising Combination Partners to Augment Bcl-2 Targeted Killing By Venetoclax

Blood (2019) 134 (Supplement_1): 807.

https://doi.org/10.1182/blood-2019-126773

Published: 2019

Journal Articles

Clonal Hematopoiesis in Erdheim-Chester Disease

Julien Haroche, MD PhD, Stéphanie Poulain, MD PhD, Alice Marceau-Renaut, PharmD, Aline Renneville, Catherine Settegrana, Karim Maloum, Damien Roos-Weil, Florence Nguyen-Khac, MD PhD, Jean Donadieu, MD, Jean-François Emile, MD PhD, Zahir Amoura, Fleur Cohen-Aubart, MD PhD

Blood (2017) 130 (Supplement 1): 3788.

https://doi.org/10.1182/blood.V130.Suppl_1.3788.3788

Published: 2017

Journal Articles

Mast Cell Density and Its Clinical Relevance in Waldenstrom's Macroglobulinemia

Richard Lemal, MD, Stephanie Poulain, MD PhD, Albane Ledoux Pilon, MD, Lauren Veronese, MD PhD, Andrei Tchirkov, MD PhD, Benjamin Lebecque, Jacques-Olivier Bay, MD PhD, Frederic Charlotte, MD, Marc G. Berger, MD PhD, Catherine Godfraind, MD PhD, Loic Ysebaert, MD PhD, Frederic Davi, Veronique Leblond, Olivier Hermine, MD PhD, Romain Guieze, MD PhD, Franck Pages, MD PhD, Olivier Tournilhac, MD PhD

Blood (2017) 130 (Supplement 1): 4028.

https://doi.org/10.1182/blood.V130.Suppl_1.4028.4028

Published: 2017

Journal Articles

A Retrospective Analysis of 450 TP53 Mutations in a Real Life Cohort of CLL from the French Innovative Leukemia Organization (FILO) Group

Blood (2017) 130 (Supplement 1): 1722.

https://doi.org/10.1182/blood.V130.Suppl_1.1722.1722

Published: 2017

Journal Articles

The Bendamustine Plus Rituximab Regimen Is Active and Safe in Previously Untreated Patients with Waldenström Macroglobulinemia, a Study on Behalf of the French Innovative Leukemia Organization (FILO)

Kamel Laribi, Stéphanie Poulain, MD, Lise Willems, MD, Fatiha Merabet, Charles Herbaux, Damien Roos-Weil, Alix Baugier de Materre, Xavier Roussel, Sabine Tricot, Jehan Dupuis, MD, Ronan Le Calloch, Benoit Bareau, Marie C Bene, PharmD,DPhil, Veronique Leblond

Blood (2017) 130 (Supplement 1): 4046.

https://doi.org/10.1182/blood.V130.Suppl_1.4046.4046

Published: 2017

Journal Articles

TP53 Mutation in Waldenstrom Macroglobulinemia

Stephanie Poulain, Christophe Roumier, MD, Elisabeth Bertrand, Aline Renneville, MD, Sabine Tricot, Aurelie Caillault Venet, Sandrine Geffroy, PhD, Morgan Nudel, Charles Herbaux, MD, Stéphanie Guidez, Claude Preudhomme, MD PhD, Xavier Leleu

Blood (2016) 128 (22): 4092.

https://doi.org/10.1182/blood.V128.22.4092.4092

Published: 2016

Journal Articles

Can Assessment of Patient Monoclonal Immunoglobulins By Heavy/Light Analysis be Used to Assign Patient Responses Analogous to IMWG Response Criteria?

Eileen Boyle, Guillemette Fouquet, Julie Lejeune, Salomon Manier, MD, Lucile Musset, Claire Bories, Remy Dulery, MD, Stéphanie Guidez, Sarah Bonnet, Brigitte Onraed, Jean-Luc Faucompre, Sabine Tricot, Stephanie Poulain, Veronique Leblond, MD PhD, Kym Snell, Xavier Leleu, MD

Blood (2015) 126 (23): 3042.

https://doi.org/10.1182/blood.V126.23.3042.3042

Published: 2015

Journal Articles

Comparison of Waldenstrom Macroglobulinemia Responses Using Immunoglobulin Heavy / Light Chain Analysis and Conventional Electrophoresis Techniques

Eileen M Boyle, MD, Julie Lejeune, Salomon Manier, MD, Lucile Musset, MD, Claire Bories, MD, Remy Dulery, Stéphanie Guidez, Sarah Bonnet, MD, Guillemette Fouquet, MD, Brigitte Onraed, MD, Jean-Luc Faucompré, MD, Sabine Tricot, MD, Stephanie Poulain, Veronique Leblond, MD PhD, Xavier Leleu, MD, Stephen Harding, PhD

Blood (2014) 124 (21): 2978.

https://doi.org/10.1182/blood.V124.21.2978.2978

Published: 2014

NARROW

Inflammatory Waldenström Macroglobulinemia is associated with clonal hematopoiesis: a multicentric cohort

Inflammatory Waldenström Macroglobulinemia Is Associated with Clonal Hematopoiesis: A Multicentric Cohort

Characteristics and Outcomes of Adult Patients with T Prolymphocytic Leukemia: A Real World Study of the French Innovative Leukemia Group (FILO)

Long-Term Follow-up of Bendamustine Plus Rituximab Regimen in 69 Treatment Naïve (TN) Patients with Waldenström Macroglobulinemia, a Study on Behalf of the French Innovative Leukemia Organization (FILO)

Preliminary Study of Ruxolitinib and Venetoclax for Treatment of Patients with T-Cell Prolymphocytic Leukemia Refractory to, or Ineligible for Alemtuzumab

BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia

Germline PAX5 mutation predisposes to familial B-cell precursor acute lymphoblastic leukemia

High frequency of clonal hematopoiesis in Erdheim-Chester disease

Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 rearrangement

Open Label Non-Randomized Phase II Study Exploring «Chemo-Free » Treatment Association with Idelalisib + Obinutuzumab in Patients with Relapsed/Refractory (R/R) Waldenstrom's Macroglobulinemia (MW), a Filo Trial: Results of the Intermediary Analysis of the Induction Phase

The Broad Spectrum of TP53 Variants in CLL: NGS Analysis of 573 Pathogenic TP53 Variants

Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia

Characterizing the Anti-Apoptotic Dependencies of T-Cell Prolymphocytic Leukemia Identifies HDAC and JAK/STAT Pathway Inhibitors As Promising Combination Partners to Augment Bcl-2 Targeted Killing By Venetoclax

Clonal Hematopoiesis in Erdheim-Chester Disease

Mast Cell Density and Its Clinical Relevance in Waldenstrom's Macroglobulinemia

A Retrospective Analysis of 450 TP53 Mutations in a Real Life Cohort of CLL from the French Innovative Leukemia Organization (FILO) Group

The Bendamustine Plus Rituximab Regimen Is Active and Safe in Previously Untreated Patients with Waldenström Macroglobulinemia, a Study on Behalf of the French Innovative Leukemia Organization (FILO)

TP53 Mutation in Waldenstrom Macroglobulinemia

Can Assessment of Patient Monoclonal Immunoglobulins By Heavy/Light Analysis be Used to Assign Patient Responses Analogous to IMWG Response Criteria?

Comparison of Waldenstrom Macroglobulinemia Responses Using Immunoglobulin Heavy / Light Chain Analysis and Conventional Electrophoresis Techniques

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only